特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
940409

注射剤と植込み型医療機器

Injectables and Implantables

出版日: | 発行: FirstWord | ページ情報: 英文 | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
注射剤と植込み型医療機器
出版日: 2020年03月18日
発行: FirstWord
ページ情報: 英文
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

制御放出 (CR) や長期放出 (PR) のための注射剤や植込み型医療機器の開発は、近年になって大きく進展してきました。その結果、患者の自由度が高まり、アドヒランス (患者の服薬遵守) の改善も見られる、という成果も出てきています。注射剤や植込み型医療機器は、今後の医薬品・医療機器の業界に大きな市場機会を与えると期待されています。他方、費用負担や規制認証、十分なエビデンスの蓄積、新興国での普及浸透など、克服すべき課題も山積しています。

当レポートでは、注射剤と植込み型医療機器 - 今日のドラッグデリバリー (薬剤送達) の重要な要素 - の最新の技術・市場動向について分析し、業界関係者へのヒアリングに基づいて、その期待されている効果や、特に効果が高い治療領域、これから解決すべき諸問題、将来の市場機会の大きさ・方向性などについて調査・考察しております。

分析概要

分析手法と目的

主要な考察事項:要約

問題点と考察内容

  • 注射剤・植込み型医療機器市場における主要な機会
    • 問題点の概要
    • 質問内容
    • 重要な考察
    • 根拠となる引用
    • 情報源
  • アドヒアランスと患者転帰の改善
  • 注射剤・植込み型医療機器から最も恩恵を受ける治療領域
  • 医療費償還の問題
  • 規制承認の問題
  • 臨床効果の実際の証拠
  • 新興国での注射剤・植込み型医療機器へのアクセス制限
  • 注射剤・植込み型医療機器の将来性
目次
Product Code: 596201653

Injectables and implantables are key to advancing patient centricity and adherence

The development of controlled and prolonged release injectable and implantable drugs has seen huge leaps forward in recent years. Increasing prevalence of chronic diseases; innovative technological advancements; growth in complex therapies such as biologics: together these factors create the potential for drug delivery solutions which offer greater patient freedom and improved adherence. Which disease areas offer the best opportunities for injectables and implantables? And what is the current position on core issues such as reimbursement, real world evidence and regulation? Now you can find out the answers to these crucial questions and more.

  • Who, what, why: Which pharma and medtech companies are making progress? What new implantable devices and novel injectable drugs have reached the market? Which therapy areas can benefit most and why?
  • The finance issues: Up-front cost is not the only consideration; long-term adherence can be significantly improved with injectables or implantables use. So, what are the factors causing payer reluctance? And how should real world evidence form part of the solution?
  • The regulatory issues: What is the current position regarding regulatory approval for injectables and implantables? And what local and global challenges must be overcome before proceeding?
  • The patient perspective: Understand how injectables and implantables make a significant difference to patient outcomes, improve adherence, and enhance quality of life.
  • The physician perspective: What more should pharma do to educate and encourage doctors to opt for injectables and implantables? Is enough being done to evidence efficacy and safety as well as patient advantages?

What to expect from this report

This report offers an up-to-date view of the fast-developing injectables and implantables market, identifying the key opportunities as well as recognising the challenges and barriers facing pharma companies looking to invest in this promising area. Delving into a wide range of issues from regulation to real world evidence to ethics and social constraints, The FutureViews Injectables and Implantables report provides the experts' view of the market to inform current and future investment strategy.

What did we do?

  • We identified 8 current issues regarding injectables and implantables
  • We explored these via secondary research to develop 15 targeted questions that we put to leading experts
  • We used all of this to identify 30 unique new insights
  • Insights are supported by 45 directly quoted comments and 60 additional source references

Example insight included in Injectables and Implantables

" If pharma is to provide access to injectables/implantables to emerging markets, it must address storage issues and social barriers. Many lower- and middle-income countries are also in regions of the world where elevated temperatures that would require cold storage for biologics. Injectables/implantables will also require aseptic facilities of manufacturing. Without adequate storage and aseptic facilities, medicines could be at risk for contamination. Additionally, manufacturers may encounter social and religious barriers to the use of some medicines such as contraceptives and vaccines: these must first be identified so that pharma can adopt storage-friendly formulations and devise culturally sensitive solutions to adoption barriers."

Example quote included in Injectables and Implantables

"Like all novel technologies entering the medical marketplace, clinician and patient adoption is indicative of a successful product. The pharma market can do a lot to help educate and provide useful information to the public regarding the benefits and patient outcomes from utilising new technologies that are entering the marketplace in the space of drug delivery. The key to knowledge is spreading awareness." Idicula Mathew , Co-Founder & CEO, Hera Health Solutions, US.

The expert panel for Injectables and Implantables

  • René Holm , Head and Scientific Director of Drug Product Development - Liquids & Parenterals at The Janssen Pharmaceutical Companies of Johnson & Johnson (J&J).
  • Idicula Mathew , CEO and co-founder of Hera Health Solutions, a pharmaceutical device start-up that specialises in the development and commercialisation of long-acting treatments through proprietary biodegradable drug delivery implants.
  • Christopher Rhodes PhD , President, CEO and Founder of Drug Delivery Experts, a boutique drug product development firm that supports pharma and biotech companies on the research, development and translation of drug delivery systems from ideation to R&D, and on to commercialisation.

Why this report is important

Improving adherence is one of the biggest challenges facing pharma; it's also perhaps the most powerful benefit of injectables and implantables. Longer lasting medication means less frequent delivery, which in turn means fewer physician appointments and fewer lapses. More discrete administering of drugs is obviously preferable for patients. Injectables and implantables offer a way forward that is far easier and more convenient for all, and enables physicians to offer a holistic response as well as improved health outcomes.

Why FirstWord reports are different

  • 100% new content: You won't find old research presented as new. Guaranteed.
  • Opinions you need to hear: We only interview experts with current, relevant experience.
  • Professional researchers: The knowledge, experience and contacts to get the answers you need.

Table of Contents

Subject synopsis

Research methodology and objectives

  • Which experts were interviewed and why?

Key insights summary

Issues and insights

  • Key opportunities within the injectables and implantables market
    • Issue summary
    • Questions
    • Key insights
    • Supporting quotes
    • Intelligence exhibits
  • Improvement in adherence and patient outcomes
    • Issue summary
    • Questions
    • Key insights
    • Supporting quotes
    • Intelligence exhibits
  • Therapy areas to benefit the most from injectables and implantables
    • Issue summary
    • Questions
    • Key insights
    • Supporting quotes
    • Intelligence exhibits
  • Reimbursement issues
    • Issue summary
    • Questions
    • Key insights
    • Supporting quotes
  • Challenges to regulatory approval
    • Issue summary
    • Questions
    • Key insights
    • Supporting quotes
    • Intelligence exhibits
  • Real-world evidence of clinical efficacy
    • Issue summary
    • Questions
    • Key insights
    • Supporting quotes
    • Intelligence exhibits
  • Limited access to injectables and implantables in emerging countries
    • Issue summary
    • Questions
    • Key insights
    • Supporting quotes
    • Intelligence exhibits
  • The future of injectables and implantables
    • Issue summary
    • Questions
    • Key insights
    • Supporting quotes
    • Intelligence exhibits
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.